Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

ACTIVE_NOT_RECRUITING

Assessment of a Chronically Implanted Parasternally Delivered EV-ICD Lead (ASCEND EV) Study

Lead Sponsor:

AtaCor Medical, Inc.

Conditions:

Ventricular Arrythmia

Ventricular Fibrillation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The ASCEND EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of the study is to evaluate the Investigational Devices thro...

Detailed Description

The primary safety endpoint is freedom from major Adverse Device Effects (ADEs) through 3-months. The primary performance endpoint is successful induced ventricular arrhythmia (IVA) test in the final ...

Eligibility Criteria

Inclusion

  • At least 18 years old
  • Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines

Exclusion

  • Participation in any concurrent clinical study without prior written approval from the Sponsor
  • Inability or unwillingness to provide informed consent to participate in the Study
  • Any known conditions which may complicate the AtaCor EV-ICD Lead System implant procedure or prevent the subject from completing protocol testing through the 3-month follow-up visit
  • Circumstances that may prevent data collection or completion of specified follow-up visits
  • Allergies to any device materials listed in the Instructions for Use (IFU)
  • Subjects on anticoagulation therapy that cannot be temporarily discontinued for the procedure
  • Known history of lung disease with FEV1 \< 1.0 Liter
  • Device Related:
  • Presence or planned use of medical devices that introduce current into the body (e.g., pacemaker, LVAD, neurostimulator, etc.)
  • Implanted with or planned implantation of any device which delivers current in the body, that may interfere with therapy delivery, including, but not limited to a pacemaker, or neurostimulator
  • Presence or planned use of a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads
  • Any known need for future MRI
  • Anatomy Related:
  • BMI ≥ 35 kg/m2
  • Structural abnormalities of the heart that may increase risk of the study procedure or an obstructed/restricted pathway into the mediastinum
  • Prior sternotomy of any type, including but not limited to median, mini or clamshell
  • Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium
  • Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis) and associated with displacement of the heart or lungs or impeded mediastinal access.
  • History of thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical treatments/conditions which may complicate the AtaCor EV-ICD Lead System implant procedure
  • Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax
  • Surgically corrected congenital heart disease (not including catheter-based procedures)
  • Cardiac Related:
  • Subjects who require permanent bradycardia pacing or cardiac resynchronization therapy
  • NYHA IV functional class in past 90 days
  • Inotropic therapy in past 180 days
  • Known history of pericardial disease, pericarditis or mediastinitis
  • Patients with a medical condition that precludes them from undergoing defibrillation testing:
  • Severe aortic stenosis
  • Current Intracardiac LA or LV thrombus
  • Severe proximal three-vessel or left main coronary artery disease without revascularization
  • Hemodynamic instability
  • Unstable angina
  • Recent stroke or transient ischemic attack (within the last 6 months)
  • Known inadequate external defibrillation
  • LVEF \< 20%
  • LVEDD \>70 mm

Key Trial Info

Start Date :

February 25 2025

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2028

Estimated Enrollment :

19 Patients enrolled

Trial Details

Trial ID

NCT06592001

Start Date

February 25 2025

End Date

December 31 2028

Last Update

December 4 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University Hospital Center Split

Split, Croatia, 21000

2

Christchurch Hospital

Christchurch, New Zealand

3

Sanatorio Italiano

Asunción, Paraguay